Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune's Vectra Testing Business to Labcorp
Share: SALT LAKE CITY, May 03, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced that it has entered into a definitive agreement to sell select operating assets and intellectual property (IP), including the Vectra® test, from Myriad Autoimmune's business unit to Labcorp (NYSE:LH) for $150 million in cash. Labcorp is a leading global life sciences company and one of the nation's largest laboratory service providers. "Our agreement with Labcorp meets our goals of ensuring broad access to the Vectra® test for patients,...